EUCTR2008-000546-31-SE进行中（未招募）不适用
A RANDOMIZED, MULTICENTRE, DOUBLE BLIND, PLACEBO CONTROLLEDSTUDY EVALUATING THE EFFICACY OF VARENICLINE IN CESSATION OFORAL TOBACCO USE
Pfizer Ltd, Ramsgate Road,Sandwich,Kent CT13 9NJ0 个研究点目标入组 432 人开始时间: 2008年5月27日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 432
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects must meet all of the following inclusion criteria to be eligible for enrollment into the study:
- •1. Have evidence of a personally signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of and has understood all pertinent aspects of the study.
- •2. Male or female daily smokeless tobacco users aged 18 years and older, who are
- •motivated to stop use of all tobacco products.
- •3. Subjects must be daily users of nicotine containing smokeless tobacco and using
- •smokeless tobacco on at least 8 occasions per day averaged over a week.
- •4. Have used smokeless tobacco for at least 1 year prior to screening with no period of abstinence >3 months in the past year.
- •5. If female, be not of childbearing potential (ie, surgically sterile or postmenopausal for at least one year), or be non-pregnant and using an acceptable method of birth control (such as implants, injectables, combined oral contraceptives, IUDs, sexual abstinence or vasectomised partner) for a least one month prior to the screening visit, and for the duration of the study period.
- •6. Subjects who are willing and able to comply with scheduled visits, treatment plan,
- •laboratory tests and other study procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Subjects with any of the following will not be included in the study:
- •1. Subjects using nicotine containing products (including smoking tobacco) other than
- •smokeless tobacco for 3 months prior to screening.
- •2. Subjects with exhaled Carbon Monoxide (CO) =10 ppm at baseline.
- •3. Subjects who have used varenicline, bupropion, or NRT within 3 months of screening.
- •4. Subjects currently or within the past 12 months requiring treatment for depression or have a current or prior history of panic disorder, psychosis, bipolar disorder or any other serious mental illness.
- •5. Subjects with a history of drug (except nicotine) or alcohol abuse or dependence within the past 12 months.
- •6. Subjects receiving concomitant treatment with another investigational drug within 30 days of the study baseline visit or with plans to take another investigational drug within 30 days of study completion (after Week 26 visit).
- •7. Subjects with an uncontrolled, unstable clinically significant medical condition (eg, renal, hepatic, endocrine, respiratory, cardiovascular, haematologic, immunologic,
- •cerebrovascular disease, diabetic or have malignancy), which, in the opinion of the
- •investigator, may interfere with the interpretation of safety or efficacy evaluations.
- •8. The contraindication of varenicline is hypersensitivity to the active substance or to any of the excipients.
研究者
相似试验
招募中
3 期
A clinical trial to assess the effect of Linaclotide in patients with chronic constipatioCTRI/2023/03/050482Dr Reddys Laboratories Limited
进行中（未招募）
1 期
EXPLORATORY EFFICACY AND SAFETY STUDY OF GLENZOCIMAB IN SARS-Cov-2-RELATED ACUTE RESPIRATORY DISTRESS SYNDROMEEUCTR2020-002733-15-FRACTICOR BIOTECH40
进行中（未招募）
不适用
A study to investigate the efficacy of CP-690,550 in subjects with moderate to severe ulcerative colitis.EUCTR2011-004578-27-ATPfizer Inc, 235 East 42nd Street, New York, New York 10017545
进行中（未招募）
1 期
A study of oral CP-690,550 as a maintenance therapy in subjects with ulcerative colitis.EUCTR2011-004580-79-HRPfizer Inc, 235 East 42nd Street, New York, New York 10017654
进行中（未招募）
不适用
A study of oral CP-690,550 as an induction therapy in subjects with moderate to severe ulcerative colitis.EUCTR2011-004579-35-PLPfizer Inc, 235 East 42nd Street, New York, New York 10017545